Frontotemporal Dementia Market By Offering (Diagnostics, Therapeutics, Supportive Care & Long-Term Care Services); By Disease Type (Behavioral-Variant Frontotemporal Dementia, Primary Progressive Aphasia, FTD With Motor Neuron Disease/Movement Disorders, Other FTD Spectrum Disorders); By Diagnostic Modality (Neuroimaging, Genetic Testing & Counseling, Neuropsychological & Language Assessment, CSF/PET/Biomarker Testing); By Genetic Profile (Sporadic FTD, GRN Mutation FTD, C9orf72-Associated FTD, MAPT-Associated FTD); By Treatment Approach (Symptomatic Management & Multidisciplinary Supportive Care, Progranulin Replacement Therapies, GRN Gene Therapy, Other Disease-Modifying Pipeline Therapies); By End User (Hospitals & Memory Clinics, Specialty Neurology Centers, Genetic Testing Laboratories & Counseling Centers, Research Institutes & Clinical Trial Sites, Home Care & Long-Term Support Providers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Frontotemporal Dementia Market: Genetic Diagnosis, Supportive-Care Spending and Progranulin Programs Redefine Commercial Opportunity

The Global Frontotemporal Dementia Market is valued at USD 3.92 billion in 2025 and is projected to reach USD 7.35 billion by 2032, expanding at a CAGR of 9.4%, according to Strategic Market Research.

 

Frontotemporal dementia, or FTD, has no FDA-approved disease-modifying treatment. Existing market revenue is generated through neurological assessment, neuroimaging, genetic testing, off-label psychiatric medicines, speech-language therapy, rehabilitation, home care and long-term support. Pharmaceutical development is concentrated in genetically defined populations, particularly patients with GRN mutations and progranulin deficiency.

 

A Small Patient Population Produces Disproportionate Care Spending

A 2025 systematic review and meta-analysis of 32 population-based studies estimated pooled FTD prevalence at 9.17 cases per 100,000 people and incidence at 2.28 cases per 100,000 person-years. Applying the pooled prevalence rate to 2026 population estimates indicates approximately 31,400 prevalent patients in the United States and around 752,000 worldwide.

The figures represent modeled clinical prevalence rather than confirmed diagnosed cases. Published U.S. estimates range from approximately 20,000 to 60,000 patients because studies use different age groups, diagnostic definitions and data sources. FTD may also remain unrecognized in countries with limited access to behavioral neurology, neuropsychological testing and genetic services.

Commercial burden is amplified by the disease’s age profile. Many patients develop symptoms between ages 45 and 64, when they are still employed and may have dependent family members. A U.S. caregiver study estimated annual FTD-related costs at USD 119,654 per patient in 2016 dollars, including USD 47,916 in direct expenses and USD 71,737 in indirect costs. Employment loss, caregiver time, home supervision and institutional care accounted for a substantial portion of the burden.

 

Psychiatric Misdiagnosis Delays Specialist Revenue

FTD frequently begins with disinhibition, apathy, impaired judgment, loss of empathy, compulsive behavior or language decline rather than conventional memory loss. Patients may first enter primary care, psychiatry, relationship counseling or general dementia services before reaching an FTD specialist.

AFTD reports an average diagnostic delay of approximately 3.6 years, while specialist studies indicate that delays in behavioral-variant FTD can extend to five or six years. Around half of patients with behavioral-variant FTD may initially receive a psychiatric diagnosis.

Delayed diagnosis restricts access to neuroimaging, genetic counseling, rehabilitation and clinical trials. It also shifts spending toward repeated psychiatric consultations and general symptom treatment without establishing the underlying disease. Referral tools that distinguish progressive behavioral change from primary psychiatric illness can therefore expand the diagnosed market without requiring an increase in underlying prevalence.

Diagnosis normally combines caregiver observations, neurological examination, neuropsychological assessment, language testing and structural brain imaging. PET imaging, cerebrospinal-fluid testing and Alzheimer’s biomarkers may be used when clinical findings remain uncertain.

 

Behavioral-Variant FTD Leads Disease-Type Revenue

Behavioral-variant FTD accounted for an estimated 57.8% of market revenue in 2025 and is projected to expand at a CAGR of 9.8% through 2032. The segment generates the highest spending because behavioral deterioration requires psychiatric assessment, neurological monitoring, caregiver supervision, safety planning and frequent medication adjustment. Primary progressive aphasia is projected to grow at approximately 10.1%, supported by recurring speech-language therapy, communication assessment and assistive communication services.

 

Symptomatic Management Retains the Largest Treatment Share

Symptomatic medicines and multidisciplinary supportive care represented approximately 72.6% of the market in 2025 and are projected to grow at a CAGR of 7.8% through 2032. Revenue is spread across generic psychiatric drugs, rehabilitation, home care and long-term support rather than FTD-specific products. Precision and disease-modifying therapies are projected to expand at approximately 14.7%, although commercial growth remains dependent on clinical success in small genetically confirmed populations.

 

Neuroimaging Anchors Diagnosis While Genetic Testing Accelerates

Neuroimaging accounted for approximately 43.5% of diagnostic-segment revenue in 2025 and is projected to grow at a CAGR of 8.6% through 2032. MRI and selected PET procedures remain central to identifying frontal or temporal degeneration and excluding competing conditions. Genetic testing is forecast to expand at approximately 13.2%, supported by broader testing recommendations, trial recruitment and the need to identify GRN, C9orf72 and MAPT mutation carriers.

 

Specialty Clinics Control the Main Treatment Pathway

Hospitals, memory centres and specialist neurology clinics held an estimated 62.4% market share in 2025 and are projected to grow at a CAGR of 9.5% through 2032. These facilities coordinate imaging, neuropsychological testing, genetic counseling and clinical trial access. Home-care and long-term-support services are projected to grow at approximately 10.1% as progressive behavioral, language, mobility and swallowing impairment increases dependence on caregivers and professional assistance.

 

Genetic Testing Becomes a Commercial Entry Point

An estimated 20% to 40% of FTD cases have some family history of dementia, motor-neuron disease or related neurological conditions. The principal genes associated with inherited FTD are GRN, C9orf72 and MAPT.

AFTD’s 2025 recommendation supports offering genetic counseling and testing to every person diagnosed with an FTD-spectrum disorder rather than limiting testing to people with a clear family history. Wider testing can identify apparently sporadic patients carrying pathogenic variants, improve clinical trial recruitment and enable relatives to receive counseling.

GRN-related FTD represents approximately 5% of all FTD cases and around 20% of familial cases. Applying the 5% share to modeled prevalence indicates a potential population of approximately 1,600 symptomatic FTD-GRN patients in the United States and about 37,600 globally.

The immediately treatable population would be smaller. Eligibility would depend on confirmed genetics, disease stage, specialist access, treatment safety, regulatory labeling and reimbursement. Because the population is small, developers must build referral networks, genetic-testing partnerships and treatment-centre capacity before approval rather than relying on conventional post-launch promotion.

 

Supportive Care Generates Current Market Revenue

There is no medicine approved specifically to slow FTD progression. Selective serotonin reuptake inhibitors and trazodone may be prescribed off-label for compulsive behavior, agitation, anxiety, depression or food-related changes. Antipsychotics may be used in severe behavioral cases but carry sedation, movement, cardiovascular and mortality risks in dementia populations.

Cholinesterase inhibitors and memantine have not demonstrated consistent FTD benefit and may worsen selected behavioral symptoms. Current pharmaceutical revenue is therefore dominated by low-cost generic medicines rather than premium disease-specific drugs.

Non-drug care accounts for a larger portion of lifetime spending. Speech-language therapy supports people with semantic and nonfluent primary progressive aphasia. Occupational therapy addresses household routines, safety and functional adaptation. Physical therapy is used when FTD overlaps with parkinsonism, progressive supranuclear palsy, corticobasal syndromes or motor-neuron disease.

Service use intensifies as patients lose communication, mobility, decision-making capacity and the ability to complete daily activities. Revenue gradually shifts from outpatient diagnosis and rehabilitation toward home support, respite care, assisted living, nutritional management and palliative services.

 

Latozinemab Failure Raises the Clinical Evidence Threshold

Latozinemab, also known as AL001, was the most advanced disease-modifying program in FTD. Alector and GSK developed the monoclonal antibody to block sortilin-mediated degradation and increase progranulin levels in patients with GRN mutations.

In October 2025, the Phase 3 INFRONT-3 trial failed to meet its clinical co-primary endpoint. Latozinemab increased plasma progranulin but did not produce clinical benefit, imaging improvement or meaningful downstream biomarker effects. Alector discontinued the associated extension study, and GSK later issued notice to terminate the companies’ collaboration in July 2026.

The result reduced confidence in therapies that rely mainly on circulating progranulin restoration. Competing products must now prove that treatment reaches relevant brain cells and changes functional decline, behavioral deterioration, language loss or neurodegeneration. Biomarker normalization without clinical improvement is unlikely to support regulatory approval or premium reimbursement.

AL101, another Alector antibody, is currently being developed for early Alzheimer’s disease and should not be treated as an active FTD pipeline asset.

 

AVB-101 Leads the Remaining Gene-Therapy Field

AviadoBio’s AVB-101 uses an AAV9 vector to deliver a functional GRN gene directly into the brain. The treatment is administered once through MRI-guided stereotactic infusions into the thalamus, with the aim of restoring progranulin across connected frontal and temporal regions.

By March 2026, the Phase 1/2 ASPIRE-FTD trial had dosed 12 participants from five countries across three dose-escalation cohorts. AviadoBio initiated a fourth cohort and reported 20 active study sites across the United States, Canada, the United Kingdom and continental Europe.

AVB-101 offers a one-time treatment model but requires neurosurgical administration, specialist infrastructure and long-term safety monitoring. A future commercial launch would therefore be concentrated in a limited number of certified treatment centres. Pricing would need to reflect the small eligible population, delivery complexity and durability of benefit.

AviadoBio regained full worldwide rights after Astellas allowed its option agreement to expire. Continued development support from the Treat FTD Fund strengthens the program’s position after the withdrawal of several competing gene-therapy assets.

 

DNL593 Creates a Repeat-Dose Progranulin Model

Denali Therapeutics’ DNL593 is an intravenously administered progranulin replacement therapy designed to cross the blood-brain barrier through the company’s transport-vehicle platform. Unlike gene therapy, DNL593 uses repeat dosing and avoids direct brain surgery.

Enrollment in its Phase 1/2 study was completed with 40 FTD-GRN participants, with clinical results expected by the end of 2026. Takeda ended its collaboration in April 2026 for strategic reasons, returning full development and commercial rights to Denali.

DNL593 and AVB-101 represent different commercial pathways. AVB-101 could generate high-value one-time treatment revenue through neurosurgical centres. DNL593 could create recurring infusion revenue but would require repeated treatment visits and sustained evidence of central nervous system exposure. Clinical efficacy, treatment durability and patient burden will determine the stronger model.

 

PBFT02 and PR006 Exits Expose Trial-Design Risk

Passage Bio discontinued the Phase 1/2 upliFT-D study of PBFT02 in May 2026 after discussions with the FDA. The agency did not support a single-arm registrational pathway and indicated that a placebo-controlled study involving sham procedures would be necessary. The required trial design created financial, operational and ethical challenges for an invasive gene-therapy program.

Eli Lilly’s Prevail Therapeutics discontinued the PR006 program in February 2026 after the studied population did not demonstrate compelling efficacy. The company stated that the decision was not linked to identified safety concerns.

These exits narrowed the FTD-GRN pipeline and reduced near-term competition for AviadoBio and Denali. They also established stricter requirements for regulator alignment, control-group design, natural-history comparisons and clinically meaningful endpoints before companies commit to expensive late-stage studies.

 

North America Holds the Largest Commercial Position

North America accounted for an estimated 46.2% of global market revenue in 2025 and is projected to grow at a CAGR of 9.2% through 2032. The region benefits from specialist FTD centres, established genetic-testing laboratories, higher rehabilitation spending, clinical trial infrastructure and organized patient advocacy.

Europe represents the second-largest market and is central to rare-disease recruitment. Multinational study networks allow developers to identify enough genetically confirmed patients for trials that cannot be completed within a single country.

Asia-Pacific is projected to record the fastest regional CAGR of approximately 10.6%. Expansion will depend on wider access to behavioral neurology, neuroimaging and genetic diagnosis. Recorded prevalence remains low in several countries because patients are frequently managed under psychiatric, Alzheimer’s or general dementia pathways.

 

Clinical Proof Determines the Next Revenue Shift

Current FTD revenue remains concentrated in diagnosis, generic symptom medicines, speech-language therapy, rehabilitation, home care and long-term support. Genetic testing is expanding the identifiable treatment population, but the pharmaceutical market will remain limited until an investigational therapy demonstrates clinically meaningful disease modification.

Latozinemab established that raising progranulin alone does not guarantee benefit. PBFT02 showed that invasive administration requires an acceptable registrational pathway. PR006 confirmed that safety without clear efficacy is insufficient.

AVB-101 and DNL593 now carry much of the near-term commercial value in FTD-GRN. Their results will determine whether market revenue begins shifting from recurring supportive care toward high-value precision treatment or remains centred on managing progressive disability.

 

Frontotemporal Dementia Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 3.92 Billion
Revenue Forecast in 2032	USD 7.35 Billion
Overall Growth Rate	CAGR of 9.4% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Offering, By Disease Type, By Diagnostic Modality, By Genetic Profile, By Treatment Approach, By End User, By Geography
By Offering	Diagnostics, Therapeutics, Supportive Care & Long-Term Care Services
By Disease Type	Behavioral-Variant Frontotemporal Dementia, Primary Progressive Aphasia, FTD With Motor Neuron Disease/Movement Disorders, Other FTD Spectrum Disorders
By Diagnostic Modality	Neuroimaging, Genetic Testing & Counseling, Neuropsychological & Language Assessment, CSF/PET/Biomarker Testing
By Genetic Profile	Sporadic FTD, GRN Mutation FTD, C9orf72-Associated FTD, MAPT-Associated FTD
By Treatment Approach	Symptomatic Management & Multidisciplinary Supportive Care, Progranulin Replacement Therapies, GRN Gene Therapy, Other Disease-Modifying Pipeline Therapies
By End User	Hospitals & Memory Clinics, Specialty Neurology Centers, Genetic Testing Laboratories & Counseling Centers, Research Institutes & Clinical Trial Sites, Home Care & Long-Term Support Providers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Market Drivers	Expansion of genetic counseling and testing for FTD-spectrum disorders Persistent spending on multidisciplinary supportive and long-term care Improved specialist referral and diagnosis, and advancement of GRN-targeted gene
Customization Option	Available upon request